enVVeno Medical Corp. Files 8-K on Shareholder Vote & Financials
Ticker: NVNO · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1661053
| Field | Detail |
|---|---|
| Company | Envveno Medical Corp (NVNO) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, financials, filing
TL;DR
enVVeno Medical Corp. filed an 8-K on 12/11/25 for shareholder votes and financials.
AI Summary
On December 11, 2025, enVVeno Medical Corp. filed an 8-K report detailing the submission of matters to a vote of security holders and financial statements. The company, formerly known as Hancock Jaffe Laboratories, Inc., is based in Irvine, California.
Why It Matters
This filing indicates important corporate actions are being taken, including votes by shareholders and the release of financial information, which are crucial for investors to assess the company's status and future prospects.
Risk Assessment
Risk Level: low — This is a routine filing for corporate actions and does not inherently signal new risks.
Key Numbers
- 001-38325 — SEC File Number (Identifies the company's filing with the SEC.)
- 33-0936180 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- enVVeno Medical Corp. (company) — Registrant
- Hancock Jaffe Laboratories, Inc. (company) — Former company name
- December 11, 2025 (date) — Date of earliest event reported
- Irvine, California (location) — Principal executive offices
FAQ
What specific matters were submitted to a vote of security holders?
The filing indicates that matters were submitted to a vote of security holders, but the specific details of these matters are not provided in this excerpt.
What is the significance of the 'Financial Statements and Exhibits' item?
This item signifies that the company is providing updated financial information and related documents as part of this filing.
When was enVVeno Medical Corp. formerly known as Hancock Jaffe Laboratories, Inc.?
The company changed its name from Hancock Jaffe Laboratories, Inc. on December 15, 2015.
Where are enVVeno Medical Corp.'s principal executive offices located?
The principal executive offices are located at 70 Doppler, Irvine, California 92618.
What is the SEC Act under which this report is filed?
This report is filed under the Securities Exchange Act of 1934.
Filing Stats: 839 words · 3 min read · ~3 pages · Grade level 11.1 · Accepted 2025-12-12 16:05:41
Key Financial Figures
- $0.00001 — ch registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Mar
Filing Documents
- form8-k.htm (8-K) — 52KB
- 0001493152-25-027482.txt ( ) — 212KB
- envvenocom-20251211.xsd (EX-101.SCH) — 3KB
- envvenocom-20251211_lab.xml (EX-101.LAB) — 33KB
- envvenocom-20251211_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
From the Filing
UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2025 enVVeno Medical Corporation (Exact name of registrant as specified in its charter) Delaware 001-38325 33-0936180 (State or other jurisdiction (Commission (I.R.S. Employer of incorporation) File Number) Identification No.) 70 Doppler Irvine , California 92618 (Address of principal executive offices) (Zip Code) (949) 261-2900 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share NVNO The NASDAQ Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.07 Submission of Matters to a Vote of Security Holders. On December 11, 2025, enVVeno Medical Corporation (the "Company") completed its 2025 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, 11,058,255 shares of the Company's common stock were represented in person or by proxy out of the 20,216,176 shares outstanding and entitled to vote as of October 17, 2025, the record date for the Annual Meeting. This constituted 54.70% of the voting power of the Company's stockholders. The voting results for each of the proposals submitted to a vote of the stockholders of the Company at the Annual Meeting are set forth below. 1. The Company's stockholders elected Matthew M. Jenusaitis and Robert A. Berman as Class II directors to serve on the Board of Directors of the Company, each to serve for a three-year term that expires as the 2028 annual meeting of stockholders or until his successor is duly elected and qualified or until their earlier death, incapacity, removal or resignation. The results of voting on the proposal are set forth below: Director Nominee Votes For Votes Withheld Broker Non-Votes Matthew M. Jenusaitis 3,468,484 1,796,053 - Robert A. Berman 4,727,591 536,946 - 2. The Company's stockholders approved on a non-binding, advisory basis the compensation of the Company's named executive officers. The results of voting on the proposal are set forth below: Votes For Votes Against Abstain Broker Non-Votes 3,194,141 1,962,414 107,982 5,793,718 3. The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of CBIZ CPAs P. C. as the Company's registered public accounting firm for the fiscal year ending December 31, 2025. The results of voting on the proposal are set forth below: Votes For Votes Against Abstain Broker Non-Votes 10,859,815 136,140 62,300 - 4. The Company's stockholders voted against the adoption of the Company's 2025 Equity Incentive Plan. As a result, the Company will not adopt the 2025 Equity Incentive Plan and the Company's 2016 Omnibus Incentive Plan will remain in full force and effect. The results of voting on the proposal are set forth below: Votes For Votes Against Abstain Broker Non-Votes 2,480,922 2,621,545 162,070 5,793,718 5. The Company's stockholders granted authority to the Company's Board of Directors to effectuate a reverse stock split of the Company's common stock at a ratio of between one-for-five and one-for-thirty-five, with such ratio to be determined at the sole discretion of the Board of Directors and with such reverse stock split to be effectuated at such time and date, if at all, as determined by the Board of Directors in its sole discretion. The results of voting on the proposal are set forth below: Votes For Votes Against Abstain Broker Non-Votes 7,312,499 1,575,554 123,250 - Item 9.